(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/013861 A3

(51) International Patent Classification[7]: A61P 37/00, 35/00, A61K 39/395, 39/385, C12N 15/866 // 5/10, C07K 16/00, G01N 33/68, (A61K 39/395, 38:19)

(21) International Application Number: PCT/US01/25203

(22) International Filing Date: 10 August 2001 (10.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/224,723	11 August 2000 (11.08.2000)	US
60/224,722	11 August 2000 (11.08.2000)	US
60/266,133	1 February 2001 (01.02.2001)	US

(71) Applicant *(for all designated States except US)*: **FAVRILLE, INC.** [US/US]; Suite 100, 10835 Altman Row, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GOLD, Daniel, P.** [US/US]; 2244 El Amigo, Del Mar, CA 92014 (US). **SHOPES, Robert, J.** [US/US]; 1639 28th Street, San Diego, CA 92102 (US).


(74) Agents: **GUISE, Jeffrey, W.** et al.; Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: METHOD AND COMPOSITION FOR ALTERING A T CELL MEDIATED PATHOLOGY



(57) Abstract: The present invention provides a method for altering a T cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the V_α or V_β region of a TCR from particular T cells from a patient having a T cell mediated pathology, and an immunoglobulin constant region. The genes encoding V_α and/or $V_{5g(b}$ regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH). Since the conjugates comprises chimeric proteins made specifically from particular T cells from a patient having T cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a T cell mediated pathology.

162162

WO 02/013861 A3

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

(88) Date of publication of the international search report:
5 December 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.